CJC-1295 (with DAC)

What it is (in plain language)
- It's a 'long-acting' version that stimulates the pituitary gland to release more Growth Hormone (GH). The term 'DAC' means that it stays in the body for several days, maintaining a constant high level of GH, unlike natural pulsations.

Why do you appear online so much
- It is highly sought after by those who want the benefits of GH (recovery, anti-ageing, fat loss) without the need for multiple daily injections. It's a favourite for long-term convenience and anti-ageing protocols.

How it is framed today (pragmatic view)
- 1) Evidence: Long history of use in performance and rejuvenation contexts. 2) Purpose: Systemic increase in IGF-1 and improvement in body composition. 3) Risk: Constant GH bleed can affect insulin sensitivity if used without breaks.

How to use this form
- Consult the internal notes on GH bleed to adjust the frequency of administration.

- Quick profile (curated by Subject 157)
- Class: Hormonal
- Status: Verified
- Use case: Anti-Aging
- Route: Injectable
- Tags: Injectable|GH|Long-Acting
- Half-life: ~6-8 Days
- Start: Slow (Sustained)
- Duration: ~7-10 days

- Mechanism (high level)
GHRH receptor agonist. The DAC group binds to serum albumin, preventing rapid degradation and maintaining high basal GH and IGF-1 levels for days.

- Evidence (what the literature covers)
RESEARCH RANGE (Clinical, Non-prescriptive):
Weekly doses of 1mg to 2mg.
Level of Evidence: B (Human studies discontinued, use in research extensive).

- Safety and harm-reduction (non-prescriptive)
Risks: Significant water retention.
Facial flushing after injection.
Insulin resistance in long-term use.
Interactions: Insulin, Corticosteroids.

- References (anchors)
- Teichman, S. L. (2006) - Prolonged stimulation of GH by CJC-1295 - https://doi.org/10.1210/jc.2005-2634
- PubMed:16352683

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.